IP Library › Granted Patent US 12,365,707
Granted Patent B2
US 12,365,707 · App. 18/742,986 · Granted Jul 22, 2025

Methods and products for genetic engineering

Inventors: Théophile Ohlmann (Tassin la Demi-Lune, FR); Philippe Mangeot (Lyons, FR); Emiliano Ricci (Lyons, FR)
Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM); Centre National De La Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon Lyon; Universite Claude Bernard Lyon
C07K14/005C12N7/00C12N9/22C12N15/102C12N15/113C07K2319/00C07K2319/43C07K2319/50C12N2310/20C12N2740/10023C12N2740/10042C12N2740/13023C12N2740/13042C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,707
App. No.
18/742,986
Granted
Jul 22, 2025
Kind
B2
Abstract

The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.

Claims (22)

1. A retrovirus-derived particle comprising one or more Cas protein(s), wherein the one or more Cas protein(s) is inside of the particle, wherein the one or more Cas protein(s) inside of the particle is the result of cleavage of a cleavable fusion protein comprising a proteolysis cleavage site located between one or more Cas proteins and a retroviral gag protein, and wherein the one or more Cas protein(s) is complexed with one or more CRISPR-Cas guide RNA(s).

2. The retrovirus-derived particle of claim 1 , wherein the Cas protein is Cas9 or an homolog or a derivative thereof.

3. The retrovirus-derived particle of claim 1 , wherein the Cas protein is Cas9.

4. The retrovirus-derived particle of claim 3 , wherein the Cas9 is from Streptococcus pyogenes (spCas9).

5. The retrovirus-derived particle of claim 1 , wherein the particle is a lentivirus-derived particle.

6. The retrovirus-derived particle of claim 3 , wherein the particle is a lentivirus-derived particle.

7. The retrovirus-derived particle of claim 4 , wherein the particle is a lentivirus-derived particle.

8. The retrovirus-derived particle of claim 1 , wherein the retrovirus-derived particle is substantially devoid of any encoding nucleic acid.

9. The retrovirus-derived particle of claim 1 , wherein the retrovirus-derived particle is devoid of any nucleic acid encoding a viral protein.

10. The retrovirus-derived particle of claim 1 , wherein the CRISPR-Cas guide RNA(s) comprise:

(a) a first CRISPR-Cas system guide RNA that hybridizes with a first target sequence of a target nucleic acid, and

(b) a second CRISPR-Cas system guide RNA that hybridizes with a second target sequence of said target nucleic acid.

11. The retrovirus-derived particle of claim 1 , wherein the retrovirus-derived particle is selected from the group consisting of Moloney murine leukemia virus-derived vector particles, Bovine immunodeficiency virus-derived particles, Simian immunodeficiency virus-derived vector particles, Feline immunodeficiency virus-derived vector particles, Human immunodeficiency virus-derived vector particles, Equine infection anemia virus-derived vector particles, Caprine arthritis encephalitis virus-derived vector particle, and Baboon endogenous virus-derived vector particles.

12. The retrovirus-derived particle of claim 4 , wherein the retrovirus-derived particle is selected from the group consisting of Moloney murine leukemia virus-derived vector particles, Bovine immunodeficiency virus-derived particles, Simian immunodeficiency virus-derived vector particles, Feline immunodeficiency virus-derived vector particles, Human immunodeficiency virus-derived vector particles, Equine infection anemia virus-derived vector particles, Caprine arthritis encephalitis virus-derived vector particle, and Baboon endogenous virus-derived vector particles.

13. The retrovirus-derived particle of claim 12 , wherein the retrovirus-derived particle is a Moloney murine leukemia virus-derived vector particle.

14. The retrovirus-derived particle of claim 12 , wherein the retrovirus-derived particle is a Human immunodeficiency virus-derived vector particle.

15. The retrovirus-derived particle of claim 12 , where the retrovirus-derived particle is a Baboon endogenous virus-derived vector particle.

16. The retrovirus-derived particle of claim 1 , wherein the retrovirus-derived particle further comprises a viral protease.

17. The retrovirus-derived particle of claim 1 , wherein the retrovirus-derived particle is devoid of any viral protease.

18. The retrovirus-derived particle of claim 1 , wherein the retroviral gag protein is derived from Moloney murine leukemia virus.

19. The retrovirus-derived particle of claim 1 , wherein the retroviral gag protein is derived from Human immunodeficiency virus.

20. The retrovirus-derived particle of claim 1 , wherein the retroviral gag protein is derived from Baboon endogenous virus.

Priority Claims (1)
EP 15306678 · Oct 20, 2015 · regional
Continuity (4)
Continuation 18130375 · Apr 3, 2023
Continuation 17174405 · Feb 12, 2021
Continuation 15769534
Related Publication 20240409588A1 · Dec 12, 2024
References Cited (155)
US 6060064A · Elizabeth et al. · 2000 [cited by applicant]
US 6204059B1 · Samulski et al. · 2001 [cited by applicant]
US 10968253B2 · Ohlmann et al. · 2021 [cited by applicant]
US 11649264B2 · Ohlmann et al. · 2023 [cited by applicant]
US 12049480B2 · Ohlmann et al. · 2024 [cited by applicant]
US 12202860B2 · Ohlmann et al. · 2025 [cited by applicant]
US 20110189159A1 · Chatterjee et al. · 2011 [cited by applicant]
US 20110262483A1 · Haynes et al. · 2011 [cited by applicant]
US 20120269840A1 · Barnett et al. · 2012 [cited by applicant]
US 20160074427A1 · Kishimoto et al. · 2016 [cited by applicant]
US 20160340661A1 · Cong et al. · 2016 [cited by applicant]
US 20160367702A1 · Hoge et al. · 2016 [cited by applicant]
US 20190010518A1 · Quake et al. · 2019 [cited by applicant]
US 20190055288A1 · Ohlmann et al. · 2019 [cited by applicant]
US 20210284697A1 · Ohlmann et al. · 2021 [cited by applicant]
US 20240109940A1 · Ohlmann et al. · 2024 [cited by applicant]
US 20240132547A1 · Ohlmann et al. · 2024 [cited by applicant]
WO WO199212237 · 1992 [cited by applicant]
WO WO1995022617 · 1995 [cited by applicant]
WO WO2010040023 · 2010 [cited by applicant]
WO WO2013068847 · 2013 [cited by applicant]
WO WO2013163628 · 2013 [cited by applicant]
WO WO2013176772 · 2013 [cited by applicant]
WO WO2014093595 · 2014 [cited by applicant]
WO WO2014131833 · 2014 [cited by applicant]
WO WO2014200659 · 2014 [cited by applicant]
WO WO2015089247 · 2015 [cited by applicant]
WO WO2015089486 · 2015 [cited by applicant]
WO WO2016073433 · 2016 [cited by applicant]
WO WO2017001570 · 2017 [cited by applicant]
WO WO2017106822 · 2017 [cited by applicant]
Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N, Ranganathan S, Ravinder N, Chesnut JD. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biot… [cited by examiner]
Abe et al., “In vitro cell-free conversion of noninfectious moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein,” J. Virol. 72(8):6356-6361 (… [cited by applicant]
Aliyari et al., “RNA-based viral immunity initiated by the Dicer family of host immune receptors,” Immunol Rev. (2009) 227(1):176-88. [cited by applicant]
Anastasov et al., Lentiviral vectors and exosomes as gene and protein delivery tools, in Methods in Molecular Biology, (2016) 1448: 49-61. [cited by applicant]
Aoki et al., “Protein transduction ny pseudotyped lentivirus-like nanoparticles,” Gene Therapy (2011) 1-6. [cited by applicant]
Brandler et al. “Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines,” Comp Immunol Microbiol Infect Dis. (2008) 31 (No. 2-3): 271-291. [cited by applicant]
Brown et al., “Assembly of hybrid bacteriophage Qbeta virus-like particles,” Biochemistry. (2009) 48(47):11155-11157. [cited by applicant]
Cai et al., “Targeted genome editing by lentiviral protein transduction of ZFN and Cas9 proteins,” Selected oral presentation (2014) A31:OR021. [cited by applicant]
Cai et al., “Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases.” (2014) Elife sciences publications Ltd. 3: 1-19. [cited by applicant]
Cass et al., “The role of Cas8 in type I CRISPR interference,” Biosci Rep. (2015) 5;35(3):e00197. (doi:10.1042/BSR20150043). [cited by applicant]
Cervera et al., “Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium,” J Biotechnol. (2013) 166(4): 152-65. [cited by applicant]
Choi JG, Dang Y, Abraham S, Ma H, Zhang J, Guo H, Cai Y, Mikkelsen JG, Wu H, Shankar P, Manjunath N. Lentivirus pre-packed with Cas9 protein for safer gene editing. Gene Ther. Jul. 2016 ;23(7) :627-33. doi: 10.1038/gt.2… [cited by applicant]
Chylinski et al. “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems,” RNA Biol. May 1, 2013; 10(5): 726-737. [cited by applicant]
Chylinski et al., “Classification and evolution of type II CRISPR-Cas systems,” Nucleic Acids Res. (2014) 42(10):6091-105. [cited by applicant]
Cong et al., “Multiplex Genome Engineering Using CRISPR/Cas Systems,” Science (2013) 339(6121): 819-823. [cited by applicant]
Cronin et al., “Altering the tropism of lentiviral vectors through pseudotyping,” Curr Gene Ther. (2005) 5(4):387-98. [cited by applicant]
Dale et al.: “Tracking and quantitation of fluorescent HIV during cell-cell transmission”, Methods. Jan. 2011; 53(1): 20-26. DOI:10.1016/J.YMETH.2010.06.018. [cited by applicant]
DiCarlo et al., “Genome engineering in [cited by applicant]
Esvelt et al., “Orthogonal Cas9 proteins for RNA-guided gene regulation and editing,” Nat Methods. (2013) 10(11):1116-21. doi: 10.1038/nmeth.2681. [cited by applicant]
Fabre et al., “CRISPR is an optimal target for the design of specific PCR assays for [cited by applicant]
Farboud et al. “Dramatic Enhancement of Genome Editing by CRISPR/Cas9 Through Improved Guide RNA Design,” Genetics, (2015) 199(4); 959-971, (doi 10.1534/genetics.115.175166). [cited by applicant]
Fenard et al., “Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells,” Mol Ther Nucleic Acids. May 7, 2013;2(5):e90. [cited by applicant]
Fontana et al., “Rabies virus-like particles expressed in HEK293 cells,” Vaccine. (2014) 32(24); 2799-804. [cited by applicant]
Fu A, Tang R, Hardie J, Farkas ME, Rotella VM. Promises and pitfalls of intracellular delivery of proteins. Bioconjug Chem. Sep. 17, 2014;25(9):1602-8. Epub Sep. 2, 2014. [cited by applicant]
Garrone et al.: “A prime-boost Strategy Using Virus-Like Particles Pseudotyped for HGV Proteins Triggers Broadly Neutralizing Antibodies in Macaques”, Science Translation Medicine. Aug. 3, 2011. vol. 3 Issue. [cited by applicant]
Gasiunas et al., “Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria,” Proc Natl Acad Sci USA. (2012) 109(39):E2579-86. [cited by applicant]
Girard-Gagnepain et al., “Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs,” Blood.(2014) 124 (8): 1221-1231. [cited by applicant]
Gong et al., “Mechanism of nonhomologous end-joining in mycobacteria: a low-fidelity repair system driven by Ku, ligase D and ligase C,” Nat Struct Mol Biol. (2005) 12(4):304-12. [cited by applicant]
Gori JL, Hsu PD, Maeder ML, Shen S, Welstead GG, Bumcrot D. Delivery and Specificity of CRISPR-Cas9 Genome Editing Technologies for Human Gene Therapy. Hum Gene Ther. Jul. 2015;26(7):443-51. [cited by applicant]
Gratz et al., “Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in [cited by applicant]
Guibingua et al., “Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells,” Mol Ther. (2002) 5(5… [cited by applicant]
Guo et al., Efficient RNA/Cas9-mediated genome editing in Xenopus tropicalis, 2014, Development. (2014) 141(3):707-14. [cited by applicant]
Hackett et al., Delivering the second revolution in seite-specififc nucleases, Elife 2014 e02904. [cited by applicant]
Hai et al., “One-step generation of knockout pigs by zygote injection of CRISPR/Cas system,” (2014) Cell Res. 24: 372-375. doi: 10.1038/cr.2014.11. [cited by applicant]
Heler et al., “Cas9 specifies functional viral targets during CRISPR-Cas adaptation,” Nature. (2015) 519(7542): 199-202. [cited by applicant]
Herbst-Kralovetz et al., “Norwalk virus-like particles as vaccines,” Expert Rev Vaccines. (2010) 9(3): 299-307. [cited by applicant]
Hill BD, Zak A, Khera E, Wen F. Engineering Virus-like Particles for Antigen and Drug Delivery. Curr Protein Pept Sci. 2018;19(1): 112-127. [cited by applicant]
Hochstrasser et al., “CasA mediates Cas3-catalyzed target degradation during CRISPR RNA-guided interference,” PNAS (2014) 111(18):6618-6623. [cited by applicant]
Hong et al., “Novel recombinant hepatitis B virus vectors efficiently deliver protein and RNA encoding genes into primary hepatocytes,” J Virol. (2013) 87(12):6615-24. [cited by applicant]
Horii et al.: “Efficient generation of knockin mice by CRISPR/Cas system”, Experimental Animals vol. 64, abstract, 2015. [cited by applicant]
Horvath et al. (Mar. 12, 2013), “RNA-guided genome editing à la carte,” [cited by applicant]
Hwang et al., “Heritable and precise zebrafish genome editing using a CRISPR-Cas system,” PLoS One. (2013) 8(7):e68708. [cited by applicant]
Jalaguier et al., “Efficient production of HIV-1 virus-like particles from a mammalian expression vector requires the N-terminal capsid domain,” PLoS One. (2011) 6(11):e28314. [cited by applicant]
Jao et al., “Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system,” Proc Natl Acad Sci U S A. (2013) 110(34):13904-13909. [cited by applicant]
Jinek et al., “A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity,” Science. (2012) 337(6096) :816-21. [cited by applicant]
Jinek et al., “RNA-programmed genome editing in human cells,” Elife. (2013) 2:e00471. doi: 10.7554/eLife.00471. [cited by applicant]
Johnston et al., “High-throughput screening identifies compounds that enhance lentiviral transduction,” Gene Ther. (2014) 21(12): 1008-20. [cited by applicant]
Kabadi et al., “Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector,” Nucleic Acids Res. (2014) 42(19):e147. [cited by applicant]
Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK. Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U SA. Oct. 11, 2011; 108(41): 16998-7003. Epub Sep. 26, 2011. [cited by applicant]
Kajigaya et al., “Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions,” Proc Natl Acad Sci USA. (1991) 88(11):4646-50. [cited by applicant]
Kang et al., “Chimeric rabies virus-like particles containing membrane-anchored GM-CSF enhances the immune response against rabies virus,” Viruses. (2015) 7(3): 1134-52. doi: 10.3390/v7031134. [cited by applicant]
Kieusseian et al., “Expression of Pitx2 in stromal cells is required for normal hematopoiesis,” Blood. (2006) 107(2):492-500. [cited by applicant]
Kim et al., “Highly efficient GENOME RNA-guided RESEARCH, genome vol. 24, editing pages in human 1012-1019, cells via 2014 delivery of purified Cas9 ribonucleoproteins,” Genome Research (2014) 24:1012-1019. [cited by applicant]
Kirnbauer et al., “Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization,” Virology. (1996) 219(1):37-44. [cited by applicant]
Kushnir et al., “Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development,” Vaccine. (2012) 31(1):58-83. [cited by applicant]
Lafountaine Justin S et al.: “Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9”, International Journal of Pharmaceutics, vol. 494, No. 1, 2015 (Aug. 13, 2015. [cited by applicant]
Latham et al., “Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins,” J Virol. (2001) 75(13):6154-65. [cited by applicant]
Li et al., “Expression and self-assembly of empty virus-like particles of hepatitis E virus,” J Virol. (1997) 71(10):7207-13. [cited by applicant]
Lin et al., “Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery,” Elife. (2014) 15;3:e04766. [cited by applicant]
Lombardo et al., “TLR4-mediated survival of macrophages is MyD88 dependent and requires TNF-alpha autocrine signalling,” J Immunol. (2007) 178(6): 3731-3739. [cited by applicant]
Ludwig et al., “Virus-like particles-universal molecular toolboxes,” Curr Opin Biotechnol. (2007) 18(6):537-45. [cited by applicant]
Ma et al., “A guide RNA sequence design platform for the CRISPR/Cas9 system for model organism genomes,” Biomed Res Int. (2013) ;2013:270805. doi: 10.1155/2013/270805. [cited by applicant]
Ma et al., “Generating rats with conditional alleles using CRISPR/Cas9,” Cell Res. (2014) 24(1):122-5. [cited by applicant]
Maeder et al., “CRISPR RNA-guided activation of endogenous human genes,” Nat Methods. (2013) 10(10):977-9. [cited by applicant]
Maetzig et al., “Retroviral protein transfer: falling apart to make an impact,” Curr Gene Ther. (2012) 12(5):389-409. [cited by applicant]
Makarova et al., “Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems,” Biol Direct. 2011; 6: 38. [cited by applicant]
Mali et al., “RNA-guided human genome engineering via Cas9,” Science. (2013) 339(6121): 823-826. [cited by applicant]
Mangeot et al. (2011, Mol Ther J Am Soc Gene Ther, vol. 19: 1656-1666. [cited by applicant]
Mangeot et al., “A universal transgene silencing method based on RNA interference,” Nucleic Acids Res. (2004) 32(12):e102. [cited by applicant]
Mangeot et al., “Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells,” J Virol. (2000) 74(18): 8307-8315. [cited by applicant]
Markowitz et al., “A safe packaging line for gene transfer: separating viral genes on two different plasmids,” J. Virol. (1988) 62(4): 1120. [cited by applicant]
Mashiko et al., “Feasibility for a large scale mouse mutagenesis by injecting CRISPR/Cas plasmid into zygotes,” Dev Growth Differ. (2014) 56(1):122-9. [cited by applicant]
Mateu MG. Assembly, Engineering and Applications of Virus-Based Protein Nanoparticles. Adv Exp Med Biol. 2016;940:83-120. Review. PubMed PMID: 27677510. [cited by applicant]
Mazurov et al., “Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles,” Viruses. (2023) 15(3):690. [cited by applicant]
Mselli-Lakhal et al., “Gene transfer system derived from the caprine arthritis-encephalitis lentivirus,” J Virol Methods. (2006) 136(1-2):177-184. [cited by applicant]
Murawski et al., “Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with No. evidence of immunopathology,” J Virol. (2010) 84(2):1110-23. [cited by applicant]
Naskalska et al., “Virus Like Particles as Immunogens and Universal Nanocarriers,” Pol J Microbiol. (2015) 64(1): 3-13. [cited by applicant]
Negre et al., “Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells,” (2000) Gene Ther. 7(19): 1613-1623. [cited by applicant]
Niu et al., “Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos,” Cell. (2014) 156(4): 836-43. [cited by applicant]
O'Connell et al., “Programmable RNA recognition and cleavage by CRISPR/Cas9,” Nature. (2014) 516(7530): 263-266. [cited by applicant]
Ogasawara et al., “Recombinant viral-like particles of parvovirus B19 as antigen carriers of anthrax protective antigen,” In Vivo. (2006) 20(3): 319-24. [cited by applicant]
Oji et al: “Complex genome editing in mouse ES cells using the CRISPR/Cas system”, Experimental Animals. [cited by applicant]
Okimoto et al., “VSV-G envelope glycoprotein forms complexes with plasmid DNA and MLV retrovirus-like particles in cell-free conditions and enhances DNA transfection,” Mol Ther. (2001) 4(3): 232-8. [cited by applicant]
Olsen, “Gene transfer vectors derived from equine infectious anemia virus,” Gene Ther. (1998) 5(11):1481-1487. [cited by applicant]
Overballe-Petersen et al., “Bacterial natural transformation by highly fragmented and damaged DNA,” Proc Natl Acad Sci USA. (2013) 110(49):19860-19865. [cited by applicant]
Peifang et al., “Enhanced activation of human T cell clones specific for virus-like particles expressing the HIV V3 loop in the presence of HIV V3 loop-specific polyclonal antibodies,” Clin Exp Immunol. (1994) 97(3): 36… [cited by applicant]
Qazi et al.: “Programmed Self-Assembly of an Active P22-Cas9 Nanocarrier System”, Molecular Pharmaceutics, vol. 13, No. 3, Mar. 7, 2016 (Mar. 7, 2016), pp. 1191-1196, XP055268807. [cited by applicant]
Qi et al., “Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression,” Cell. (2013) 152(5): 1173-83. [cited by applicant]
Quan et al., “Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection,” Virology. (2012) 430(2): 127-35. [cited by applicant]
Ramakrishna et al: “Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide Rna”, Genome Research, vol. 24, pp. 1020-1027, Apr. 2, 2014. [cited by applicant]
Ran et al., “Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity,” Cell. (2013) 154(6): 1380-9. [cited by applicant]
Rasmussen et al., “Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus,” Virology. (1990) 178(2): 435-51. [cited by applicant]
Richter et al. (Jul. 12, 2013), “Exploiting CRISPR/Cas: Interference Mechanisms and Applications,” Int. J. Mol. Sci. (2013), 14, in 14 pages. [cited by applicant]
Rohovie MJ, Nagasawa M, Swartz JR. Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery. Bioeng Transl Med. Jan. 19, 2017;2(1):43-57. [cited by applicant]
Ruffing et al., “Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells,” J Virol. (1992) 66(12):6922-6930. [cited by applicant]
Saenz et al., “Feline immunodeficiency virus-based lentiviral vectors,” Cold Spring Harb Protoc. (2012) 2012(1):71-6. [cited by applicant]
Saenz et al., “Production and harvest of feline immunodeficiency virus-based lentiviral vector from cells grown in T75 tissue-culture flasks,” Cold Spring Harb Protoc. (2012) 2012(1):124-125. [cited by applicant]
Saenz et al., “Production, harvest, and concentration of feline immunodeficiency virus-based lentiviral vector from cells grown in CF10 or CF2 devices,” Cold Spring Harb Protoc. (2012) 2012(1): 118-23. [cited by applicant]
Sakuma et al., Multiplex genome engineering in human cells using all in one CRISPR/Cas9 vector system. Sci Rep. 4: 5400, 2014. [cited by applicant]
Samulski et al., “Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression,” J Virol. (1989) 63(9): 3822-8. [cited by applicant]
Sanjana et al., “Improved vectors and genome-wide libraries for CRISPR screening,” Nat Methods. (2014) 11(8):783-784. [cited by applicant]
Shalem et al., “Genome-scale CRISPR-Cas9 knockout screening in human cells,” Science. (2014) 343(6166): 84-87. [cited by applicant]
Shalem et al., “Genome-scale CRISPR-Cas9 knockout screening in human cells,” Science. (2014) 343(6166): 84-87. Supplementary Information (78 pages). [cited by applicant]
Sharma et al., “Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents,” Proc … [cited by applicant]
Sinkunas et al., “Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system,” EMBO J. (2011) 30(7):1335-42. [cited by applicant]
Skipper et al., “Delivering the goods for genome engineering and editing.” Hum Gene Therapy. (2015) 26(8):486-497. [cited by applicant]
Sun et al.: 11 Self-Assembled DNA Nanoclews for the Efficient Delivery of CRISPR-Cas9 for Genome Editing11 , Angewandte Chemie International Edition, vol. 54, No. 41, Oct. 5, 2015 (Oct. 5, 2015). [cited by applicant]
Takahara et al., “A new retrovirus packaging cell for gene transfer constructed from amplified long terminal repeat-free chimeric proviral genes,” J Virol. (1992) 66(6): 3725-3732. [cited by applicant]
Tome-Amat et al., “Secreted production of assembled Norovirus virus-like particles from Pichia pastoris,” Microb Cell Fact. (2014) 13:134-142. [cited by applicant]
Voelkel C, Galla M, Maetzig T, Warlich E, Kuehle J, Zychlinski D, Bode J, Cantz T, Schambach A, Baum C. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci U SA. Apr. 27, 2010; 107(17):7805-10. doi: … [cited by applicant]
Wagner et al., “Transfer of genes into embryonal carcinoma cells by retrovirus infection: efficient expression from an internal promoter,” EMBO J. (1985) 4(3):663-6. [cited by applicant]
Walpita et al., “Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract,” PLoS One. (2015) 10(7): e0130755. [cited by applicant]
Wang et al., “One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering,” Cell. (2013) 153(4):910-918. [cited by applicant]
Wang et al., “Virus-like particles for the prevention of human papillomavirus-associated malignancies,” Expert Rev Vaccines. (2013) 12(2):129-41. [cited by applicant]
Yang et al., “Effective gene targeting in rabbits using RNA-guided Cas9 nucleases,” J Mol Cell Biol. (2014) 6(1):97-99. [cited by applicant]
Yang et al., “HIV-1 virus-like particles produced by stably transfected [cited by applicant]
Yee et al., “A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes,” Proc Natl Acad Sci USA. (1994) 91(20):9564-9568. [cited by applicant]
Yee et al., “Generation of high-titer pseudotyped retroviral vectors with very broad host range,” Methods Cell Biol. (1994);43 Pt A: 99-112. [cited by applicant]
Zeltins, Andris. “Construction and characterization of virus-like particles: a review.” Mol Biotechnol. (2013) 53(1): 92-107. [cited by applicant]
Zetsche et al., “Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system,” Cell. (2015) 163(3):759-71. http://dx.doi.org/10.1016/j.cell.2015.09.038. [cited by applicant]
Zhao et al., “BPV1 E2 protein enhances packaging of full-length plasmid DNA in BPV1 pseudovirions,” Virology. (2000) 272(2): 382-93. [cited by applicant]
Zhu et al., “CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing systems,” PLoS One. (2014) 9(9):e108424. [cited by applicant]
Zuris et al., “Efficient delivery of genome-editing proteins in vitro and in vivo,” Nat Biotechnol (2015) 33(1):73-80. [cited by applicant]
Zuris, John A., et al. “Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo.” Nature biotechnology 33.1 (2015): 73-80. [cited by applicant]